Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
10 S&P 500 Stocks Are Practically Immune To More Fed Rate Hikes
08:00am, Monday, 06'th Mar 2023
Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.
2 Reasons to Buy Moderna Stock, and 1 Reason to Sell
05:31am, Monday, 06'th Mar 2023
Moderna's multi-year run of earning billions from its COVID-19 vaccine is winding down. It still has a massive pipeline of other pharmaceutical offerings that are full of promising projects.
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
12:38pm, Sunday, 05'th Mar 2023 The Motley Fool
Can Lumen Technologies, Moderna, Baxter International, and Pfizer recover this year?
Better Growth Stock: Moderna vs. CRISPR Therapeutics
10:30am, Sunday, 05'th Mar 2023 The Motley Fool
Both stocks are ripe for a rebound.
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
07:38am, Sunday, 05'th Mar 2023
Lumen's slowing growth, high debt, and dividend cut spooked the bulls. Moderna and Pfizer both face tough post-pandemic slowdowns.
Better Growth Stock: Moderna vs. CRISPR Therapeutics
05:30am, Sunday, 05'th Mar 2023
Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.
Should You Give Up on Novavax?
07:00pm, Friday, 03'rd Mar 2023 The Motley Fool
After a spectacular 2020 performance, Novavax's shares have plummeted.
Is Moderna Stock a Buy Now?
12:30pm, Friday, 03'rd Mar 2023 The Motley Fool
The company is looking to transition beyond its COVID-19 vaccine, and that could mean a bumpy ride for investors.
Is Moderna Stock a Buy Now?
07:30am, Friday, 03'rd Mar 2023
The company is looking to transition beyond its COVID-19 vaccine, and that could mean a bumpy ride for investors.
Moderna May Be Just Getting Started in This Big Market
07:00pm, Thursday, 02'nd Mar 2023 The Motley Fool
We still may be able to count on Moderna for blockbuster revenue -- and over the long term.
Why This Moderna Analyst Is Very Bullish
04:54pm, Thursday, 02'nd Mar 2023 Benzinga
Shares of Moderna Inc (NASDAQ: MRNA) have lost almost 24% year to date.
While the prospects of the Covid-vaccine seem to be waning, data from the cancer vaccine is impressive, according to RBC Capital
Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2023
03:00pm, Thursday, 02'nd Mar 2023 Benzinga
Upgrades
According to Mizuho, the prior rating for DT Midstream Inc (NYSE:DTM) was changed from Neutral to Buy. In the fourth quarter, DT Midstream showed an EPS of $0.93, compared to $0.89 from the y
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
02:00pm, Thursday, 02'nd Mar 2023 Zacks Investment Research
Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Moderna May Be Just Getting Started in This Big Market
02:00pm, Thursday, 02'nd Mar 2023
We still may be able to count on Moderna for blockbuster revenue -- and over the long term.
Nasdaq, S&P Futures Slide As Bond Yields Stay Above 4%: Economic Signals Ominous But Don't Panic Yet, Says Analyst
11:52am, Thursday, 02'nd Mar 2023 Benzinga
The mood on Wall Street continues to be somber on Thursday, as risk aversion continues to rule high. Some positive earnings could serve to cushion any potential slide even as traders look ahead to the
